CDSCO Panel Rejects Akum Pharma’s Clonazepam-Duloxetine Combination Drug
New Delhi: Reviewing the justification provided by the drug major Akum Pharmaceutical concerning the fixed-dose combination (FDC) Clonazepam plus Duloxetine Hydrochloride, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has rejected approval for the proposed FDC. This came after the drug maker Akum Pharmaceutical presented the proposal along with justification […]